Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
life sciences
national blog main
onpattro
4
×
patisiran
akcea therapeutics
alnylam pharmaceuticals
boston
clinical trials
drugs
fda
inotersen
national top stories
new york blog main
new york top stories
pfizer
san diego blog main
san diego top stories
tafamidis
hereditary transthyretin amyloidosis
rna interference
acute hepatic porphyrias
akin akinc
aminolevulinic acid
andrew fire
anylam pharmaceuticals
cardiomyopathy
craig mello
european medicines agency
givosiran
harvard pilgrim health care
institute for clinical and economic review
john maraganore
neuropathy
new york
nobel prize
paul matteis
san francisco blog main
san francisco top stories
What
alnylam
4
×
drug
fda
medicine
rnai
ago
approved
interference
pharmaceuticals
rna
afternoon
akcea
alnylam’s
amyloidosis
approval
approves
attr
available
battle
cells
debilitating
disease
ema
employ
europe
follows
gene
genetic
gets
harmful
history
hits
indicated
landmark
make
making
medicines
method
mute
nod
Language
Current search:
alnylam
×
onpattro
×
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug